Sensus Healthcare (SRTS) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $2.3 million, down from $7.3 million in Q2 2025, primarily due to a lower number of units sold (11 units vs. 19 units in the prior year).

Cost of Sales: $1.5 million, compared to $4.4 million in the prior year.

Gross Profit: Approximately $0.8 million, down from $2.9 million; gross margin decreased to 34.8% from 39.7%.

Operating Expenses: General and administrative expenses were $1.8 million (down from $2 million), while selling and marketing expenses were $1.1 million (down from $1.4 million).

Adjusted EBITDA: -$3 million, compared to -$1.8 million in Q2 2025.

Net Loss: $8.7 million ($0.53 per share), compared to a net loss of $1 million ($0.06 per share) in the prior year.

Cash Position: $15.2 million in cash and cash equivalents, down from $18.3 million at the end of Q1 2026.

2Strategic Updates and Business Highlights

The company faced delays in revenue recognition due to third-party financing issues, which affected the recognition of 19 units. However, 8 units have since been approved for Q3.

Sensus Healthcare is focusing on five strategic priorities: education and training, accelerating customer adoption, expanding recurring revenue, broadening commercial reach, and driving towards profitability.

The introduction of dedicated CPT codes has improved reimbursement clarity, leading to increased interest and engagement from independent dermatology practices and larger healthcare systems.

Internationally, there is growing interest in SRT, particularly in the Asia-Pacific region, with significant opportunities in Australia and New Zealand.

3Forward Guidance and Outlook

Management is optimistic about the second half of 2026, expecting stronger performance driven by a growing pipeline and increased commercial activity.

The company anticipates converting more opportunities into revenue and is focused on expanding its customer base and utilization of existing systems.

4Bad News, Challenges, or Points of Concern

The significant drop in revenue year-over-year raises concerns about sales momentum and reliance on third-party financing.

The company will no longer work with the bank that caused delays in financing, which may impact future financing arrangements.

The net loss has widened compared to the previous year, indicating ongoing financial challenges.

The largest former customer is still not purchasing units, which may affect future revenue streams.

5Notable Q&A Insights

Management confirmed that the 11 units sold in Q2 included 6 direct sales, with expectations for increased unit sales in Q3 and Q4.

The Fair Deal Agreement model is seeing a balanced mix of sales and recurring revenue, indicating flexibility in customer purchasing preferences.

There is optimism about Sensus Link activations contributing to recurring revenue, with a focus on enhancing customer engagement through software updates.

Proposed increases in hospital reimbursement rates for SRT are seen as positive, while no immediate negative impacts on dermatology reimbursement were noted. Overall, while Sensus Healthcare faces challenges in revenue recognition and customer relationships, there are signs of improving commercial momentum and a strategic focus on expanding its market presence.